This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07437560 |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hudson Biotech |
| Enrollment | 60 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | NonSegmental Vitiligo; Nonsegmental Vitiligo (Stable) |
| Interventions | Melanotan II (MT-II); Placebo; Narrowband UV-B (NB-UVB) phototherapy |
| Start | Feb 2, 2026 |
| Primary completion | Feb 14, 2027 |
| Study completion | Feb 17, 2028 |
| Results posted | Not yet |
| Registry last updated | Feb 27, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from baseline in Vitiligo Area Scoring Index (VASI) total score | 24 Weeks |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
